Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P30CA014520 | U.S. NIH Grant/Contract | View source | |
| 1R37CA226526-01A1 | U.S. NIH Grant/Contract | View source | |
| NCI-2019-06343 | Registry Identifier | NCI Trial ID | |
| A533400 | Other Identifier | UW Madison | |
| SMPH\UWCCC\GENERAL | Other Identifier | UW Madison | |
| Protocol Version 3/24/24 | Other Identifier | UW Madison | |
| UW15068 | Other Identifier | OnCore ID |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PMMTB | This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PMMTB (Precision Medicine Molecular Tumor Board) | Other | PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of acceptance of molecular tumor board recommendations | How often the molecular tumor board's recommendations are accepted | Up to 5 years |
| Benefit from PMMTB recommended treatment | Whether patients benefit from PMMTB recommended treatment | Up to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of mutations with protein overexpression | Correlate mutations identified in tumor tissue with protein overexpression | Up to 5 years |
| Correlations of mutations with circulating tumor DNA |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This study will include all patients age ≥18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. It will require each patient to have the ability to understand and willingness to sign a written informed consent document.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cancer Connect | Contact | 8006228922 | clinicaltrials@cancer.wisc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Dustin Deming, MD | University of Wisconsin, Madison | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Wisconsin Carbone Cancer Center | Recruiting | Madison | Wisconsin | 53792 | United States |
Not provided
| Label | URL |
|---|---|
| UW Carbone Cancer Center Home Page | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Subjects will be asked to give one blood sample and up to two tissue samples (one at diagnossi & one at progression of treatment, which are both standard clinical procedures).
Correlate mutations identified in tumor tissue with circulating tumor DNA
| Up to 5 years |
| Correlations of mutations with spheroid culture investigations | Correlate mutations identified in tumor tissue with spheroid culture investigations | Up to 5 years |